Tarsons Products Limited has announced a key senior management appointment, naming Mr. Mani Kalyan Dusi as Head-Revenue (India & APAC) in the Senior Management Personnel category. The appointment, disclosed to stock exchanges on April 14, 2026, under Regulation 30 of SEBI Listing Regulations, reflects the company's strategic focus on strengthening its leadership team in key growth markets.

Appointment Details and Timeline

The Board of Directors approved Mr. Dusi's appointment based on the recommendation of the Nomination & Remuneration Committee. He is expected to join the company on or before May 20, 2026, taking on the critical role of driving revenue operations across India and the Asia-Pacific region.

Professional Background and Expertise

Mr. Mani Kalyan Dusi brings over 18 years of extensive experience in the life sciences, pharmaceuticals, and academic sectors across the APAC region. His professional expertise encompasses commercial leadership, strategic marketing, go-to-market strategies, and P&L management, with a demonstrated track record of driving business growth and operational excellence.

Currently serving as Associate Director and Head – Commercial Enablement (APAC) at Merck Life Science, he leads regional strategy and business development initiatives. His career includes key leadership roles at both Merck Life Science and Thermo-Fisher Scientific, where he successfully managed large portfolios, led cross-functional teams, and strengthened customer-centric innovation and market expansion efforts.

Key Qualifications and Achievements

Mr. Dusi is recognized for his data-driven approach, digital enablement capabilities, and ability to build high-performing teams. His professional accomplishments include:

• Receipt of the AAA Award for marketing leadership at Merck
• Active contribution to diversity, equity, and inclusion (DEI) initiatives
• M.Sc. in Biochemistry (University First Rank) from Andhra University
• Executive leadership education completion at INSEAD

Strategic Implications

The appointment of Mr. Dusi as Head-Revenue for India & APAC underscores Tarsons Products' commitment to strengthening its commercial operations in key growth markets. His extensive experience in the life sciences sector and proven expertise in regional strategy development align with the company's operational focus in laboratory and scientific equipment manufacturing.

The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, ensuring transparency in senior management changes for stakeholders and regulatory authorities.

Tarsons Products Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The regulatory filing was made on April 09, 2026, to both BSE Limited and National Stock Exchange of India Limited.

Regulatory Compliance Certificate

The certificate was issued by KFin Technologies Limited, serving as the Registrar and Share Transfer Agent for Tarsons Products Limited. The document confirms that all required details regarding securities dematerialized and rematerialized during the quarter have been properly furnished to the stock exchanges where the company's shares are listed.

Stock Exchange Notification

The compliance certificate was formally submitted to both major Indian stock exchanges where Tarsons Products shares are traded. The company maintains its listing on BSE with scrip code 543399 and on NSE under the symbol TARSONS.

Depositories Confirmation

KFin Technologies Limited, as the appointed Registrar and Share Transfer Agent, issued separate certificates to both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). These certificates, dated April 01, 2026, were signed by Bhaskar Roy, Deputy Vice President at KFin Technologies Limited.

Corporate Governance

The filing demonstrates Tarsons Products Limited's commitment to maintaining regulatory compliance and transparent corporate governance practices. Santosh Kumar Agarwal, who serves as CFO, Company Secretary and Compliance Officer with ICSI Membership No. A44836, signed the submission on behalf of the company.

This quarterly certification process ensures that all securities transactions involving dematerialization and rematerialization are properly documented and reported to relevant regulatory authorities, maintaining the integrity of the securities market infrastructure.